12 Participants Needed

Drug Interaction Study in Healthy Subjects

(529 DDI ITZ Trial)

AC
Overseen ByABBVIE CALL CENTER
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: AbbVie
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This study is to assess the change of itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety, and tolerability of a single dose of icalcaprant in healthy participants.

Research Team

AI

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

This trial is for healthy adults. Specific details about who can join are not provided, but typically participants must meet certain health standards and not be taking conflicting medications.

Inclusion Criteria

Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
I am generally healthy based on recent medical exams and tests.

Exclusion Criteria

I have not taken icalcaprant in the last 90 days.
History of any clinically significant sensitivity or allergy to any medication or food
I have a condition or had surgery that could affect my stomach or intestine's function.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive oral Icalcaprant with Itraconazole for up to 8 days

1 week

Follow-up

Participants are monitored for safety and effectiveness after treatment

30 days

Treatment Details

Interventions

  • Icalcaprant
  • Itraconazole
Trial Overview The study is testing how the drug Icalcaprant behaves in the body when taken with another drug called Itraconazole. Participants will receive a single dose of Icalcaprant to see if there's any change when it's combined with a strong CYP3A inhibitor like Itraconazole.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Icalcaprant with ItraconazoleExperimental Treatment2 Interventions
Participants will receive oral Icalcaprant with Itraconazole up to 8 days and then followed for 30 days.

Find a Clinic Near You

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials
1,079
Recruited
535,000+
Founded
2013
Headquarters
North Chicago, USA
Known For
Immunology treatments
Top Products
Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael profile image

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security